Kajian klinikal Melanoma di Delaware
6 kajian untuk Melanoma sedang mencari peserta di lokasi di Delaware.
Bandar di Delaware
Teks kajian rasmi (Bahasa Inggeris)
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05136196A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
- Alfred I duPont Hospital for Children, Wilmington
Mengambil pesertaFasa 2
Sehingga umur 25 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07621614Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Beebe Medical Center, Lewes
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- dan 4 lagi
Mengambil pesertaFasa 3
Umur 75 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07068074Project: Every Child for Younger Patients With Cancer
- Alfred I duPont Hospital for Children, Wilmington
Mengambil pesertaKajian pemerhatian
Sehingga umur 25 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT02402244Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- dan 1 lagi
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Newark
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.